Home > Cardiology > HFA 2022 > EMPULSE: empagliflozin delivers rapid and clinically meaningful decongestion

EMPULSE: empagliflozin delivers rapid and clinically meaningful decongestion

Presented By
Prof. Piotr Ponikowski, Medical University of Wroclaw, Poland
Conference
HFA 2022
Trial
Phase 3, EMPULSE
The initiation of empagliflozin therapy in patients who were hospitalised for acute heart failure (HF) was associated with early, clinically meaningful, and sustainable decongestion. This was the main outcome of the EMPULSE trial [1]. The EMPULSE trial (NCT04157751) randomised 530 patients with stabilised acute HF to empagliflozin or placebo. Empagliflozin outperformed placebo concerning the primary endpoint of this study, a composite of all-cause death, HF events, and Kansas City Cardiomyopathy Questionnaire - Total Symptom Score (KCCQ-TSS) change from baseline [2]. The current analysis assessed the decongestive effects of empagliflozin compared to placebo. “This analysis is important as congestion presents the main reason for hospitalisation in patients with acute decompensated HF,” added Prof. Piotr Ponikowski (Medical University of Wroclaw, Poland) [3]. Weight ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on